Hawaii Biotech   Report issue

For profit Phase 1
Founded: Aiea HI United States (1982)
Status: Acquired by Merck (2011)

Organization Overview

First Clinical Trial
2008
NCT00707642
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Hawaii Biotech, Inc.

Active Ingredients

Drugs in Phase 1 Trials (3)

aluminum hydroxide (Gaviscon) (1 trial)

hbv-001 d1 (1 trial)

wn-80e (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dengue (Phase 1)

Virus Diseases (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 3